logo

For the Inventor, By the Inventor

Groton, MA, United States of America

David Lawrence Firman Gray

USPTO Granted Patents = 20 

 

Average Co-Inventor Count = 9.2

ph-index = 5

Forward Citations = 67(Granted Patents)


Company Filing History:

goldMedal20 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 2014-2024

Loading Chart...
Loading Chart...
20 patents (USPTO):Explore Patents
1. 11964961 - Heteroaromatic compounds and their use as dopamine D1 ligands (2024-04-23),
2. 11014909 - Heteroaromatic compounds and their use as dopamine D1 ligands (2021-05-25),
3. 10696658 - Heteroaromatic compounds and their use as dopamine D1 ligands (2020-06-30),
4. 10421744 - Heteroaromatic compounds and their use as dopamine D1 ligands (2019-09-24),
5. 10093655 - Heteroaromatic compounds and their use as dopamine D1 ligands (2018-10-09),
6. 10077272 - Heteroaromatic compounds and their use as dopamine D1 ligands (2018-09-18),
7. 9868744 - Heteroaromatic compounds and their use as dopamine D1 ligands (2018-01-16),
8. 9856263 - Heteroaromatic compounds and their use as dopamine D1 ligands (2018-01-02),
9. 9850232 - Heteroaromatic compounds and their use as dopamine D1 ligands (2017-12-26),
10. 9822097 - Heteroaromatic compounds and their use as dopamine D1 ligands (2017-11-21),
11. 9745317 - Heterocyclic compounds and their use as dopamine D1 ligands (2017-08-29),
12. 9688698 - Heteroaromatic compounds and their use as dopamine D1 ligands (2017-06-27),
13. 9617275 - Heteroaromatic compounds and their use as dopamine D1 ligands (2017-04-11),
14. 9540352 - Substituted 1,7-naphthyridines as dopamine D1 ligands (2017-01-10),
15. 9527843 - Heteroaromatic compounds and their use as dopamine D1 ligands (2016-12-27),

Title: David Lawrence Firman Gray: Innovator in Neuropharmacology

Introduction

David Lawrence Firman Gray, based in Groton, MA, is a prominent inventor with 20 patents to his name. His innovative work primarily focuses on neuropharmacology, particularly the development of compounds that address various mental health and cognitive disorders.

Latest Patents

Among his latest contributions to the field are patents related to heteroaromatic compounds, which serve as dopamine D1 ligands. These compounds are designed to offer potential treatments for a range of D1-mediated disorders, including schizophrenia, cognitive impairment, attention-deficit hyperactivity disorder (ADHD), and Parkinson's disease. The present invention encompasses compounds of Formula I, their pharmaceutically acceptable salts, and the processes involved in their preparation, highlighting a significant advancement in treating complex neurological conditions.

Career Highlights

David Gray is currently associated with Pfizer Corporation, where his research and innovations continue to make a considerable impact. His extensive patent portfolio reflects his dedication to improving therapeutic approaches for neurological and psychiatric disorders. Gray's expertise in the field has established him as a key figure in neuropharmacology research.

Collaborations

Throughout his career, David has collaborated with several esteemed colleagues, including Jennifer Elizabeth Davoren and Ivan Viktorovich Efremov. These collaborations have not only fostered innovation but have also contributed to the development of breakthrough treatments that aim to improve patient outcomes.

Conclusion

David Lawrence Firman Gray stands out as a notable inventor in the pharmaceutical sector, particularly in the realm of neuropharmacology. His contributions, encapsulated in his patents, signal a commitment to addressing the persistent challenges associated with mental health and cognitive disorders, ultimately paving the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…